Burka JM, Bower KS, et al. 2005. The effect of fourth-generation ﬂuoroqui- nolones gatiﬂoxacin and moxiﬂoxacin on epithelial healing following photorefractive keratectomy. Am J Ophthalmol, 140:83–7. Burka JM, Bower KS, et al. 2007. The effect of moxiﬂoxacin and gatiﬂoxacin on long-term visual outcomes following photorefractive keratectomy. J Refract Surg, 23:414–7. Caeiro JP, Iannini PB. 2003. Moxiﬂoxacin (Avelox): a novel ﬂuoroquino- lone with a broad spectrum of activity. Expert Rev Anti Infect Ther, 1:363–70. Cekic O, Batman C, et al. 1999a. Penetration of oﬂoxacin and ciproﬂoxa- cin in aqueous humor after topical administration. Ophthalmic Surg Lasers, 30:465–8. Cekic O, Batman C, et al. 1999b. Human aqueous and vitreous humour levels of ciproﬂoxacin following oral and topical administration. Eye, 13:555–8. Chang Lin JE, Welty D. 2006. Ocular pharmacokinetics of moxiﬂoxacin after topical treatment of animals and humans. Surv Ophthalmol, 51:530; author reply 530–1. Chaudhry NA, Flynn Jr HW, et al. 1999. Emerging ciproﬂoxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol, 128:509–10. Costello P, Bakri SJ, et al. 2006. Vitreous penetration of topical moxiﬂoxacin and gatiﬂoxacin in humans. Retina, 26:191–5. Dalhoff A, Schmitz FJ. 2003. In vitro antibacterial activity and pharmacody- namics of new quinolones. Eur J Clin Microbiol Infect Dis, 22:203–21. Deramo VA, Lai JC, et al. 2006. Acute endophthalmitis in eyes treated prophylactically with gatiﬂoxacin and moxiﬂoxacin. Am J Ophthalmol, 142:721–5. Domagala JM. 1994. Structure-activity and structure-side-effect rela- tionships for the quinolone antibacterials. J Antimicrob Chemother, 33:685–706. Donaldson KE, Marangon FB, et al. 2006. The effect of moxiﬂoxacin on the normal human cornea. Curr Med Res Opin, 22:2073–80. Donnenfeld E, Perry HD, et al. 2004. A comparison of the fourth-generation ﬂuoroquinolones gatiﬂoxacin 0.3% and moxiﬂoxacin 0.5% in terms of ocular tolerability. Curr Med Res Opin, 20:1753–8. Donnenfeld ED, Kim T, et al. 2005. ASCRS White Paper: Management of infectious keratitis following laser in situ keratomileusis. J Cataract Refract Surg, 31:2008–11. Drlica K, Malik M. 2003. Fluoroquinolones: action and resistance. Curr Top Med Chem, 3:249–82. Durrie DS, Trattler W. 2005. A comparison of therapeutic regimens con- taining moxiﬂoxacin 0.5% ophthalmic solution and gatiﬂoxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocul Pharmacol Ther, 21:236–41. Endophthalmitis Vitrectomy Study Group.1995. Results of the Endophthal- mitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacte- rial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol, 113:1479–96. Freitas D, Alvarenga L, et al. 2003. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology, 110:276–85. Fuller JJ, Lott MN, et al. 2007. Vitreal penetration of oral and topical moxiﬂoxacin in humans. Am J Ophthalmol, 143:338–40. Garcia-Saenz MC, Arias-Puente A, et al. 2001. Human aqueous humor levels of oral ciproﬂoxacin, levoﬂoxacin, and moxiﬂoxacin. J Cataract Refract Surg, 27:1969–74. Goldstein MH, Kowalski RP, et al. 1999. Emerging ﬂuoroquinolone resistance in bacterial keratitis:a 5-year review. Ophthalmology, 106:1313–8. Griggs DJ, Marona H, et al. 2003. Selection of moxiﬂoxacin-resistant Staphylococcus aureus compared with ﬁve other ﬂuoroquinolones. J Antimicrob Chemother, 51:1403–7. Gupta V, Gupta A, et al. 2003. Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology, 110:1744–9. Haimann MH, Weiss H, et al. 1996. The Endophthalmitis Vitrectomy Study. Arch Ophthalmol, 114:1025; author reply 1026–7. Clinical Ophthalmology 2008:2(1) Moxiﬂoxacin hydrochloride ophthalmic solution Han DP, Wisniewski SR, et al. 1996. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol, 122:1–17. Hariprasad SM, Blinder KJ, et al. 2005. Penetration pharmacokinetics of topically administered 0.5% moxiﬂoxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol, 123:39–44. Hariprasad SM, Shah GK, et al. 2005. Determination of aqueous and vitreous concentration of moxiﬂoxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg, 31:2142–6. Hariprasad SM, Shah GK, et al. 2006. Vitreous and aqueous penetration of orally administered moxiﬂoxacin in humans. Arch Ophthalmol, 124:178–82. Harper T, Miller D, et al. 2007. In vitro efﬁcacy and pharmacodynamic indices for antibiotics against coagulase-negative Staphylococcus endophthalmitis isolates. Ophthalmology, 114:871–5. Hermsen ED, Hovde LB, et al. 2005. Mutant prevention concentrations of ABT-492, levoﬂoxacin, moxiﬂoxacin, and gatiﬂoxacin against three common respiratory pathogens. Antimicrob Agents Chemother, 49:1633–5. Hoﬂing-Lima AL, de Freitas D, et al. 2005. In vitro activity of ﬂuoro- quinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil. Cornea, 24:730–4. Hooper DC. 2001a. Emerging mechanisms of ﬂuoroquinolone resistance. Emerg Infect Dis, 7:337–41. Hooper DC. 2001b. Mechanisms of action of antimicrobials: focus on ﬂuoroquinolones. Clin Infect Dis, 32(Suppl 1):S9–S15. Hwang DG. 2004. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic ﬂuoroquinolones. Surv Ophthalmol, 49(Suppl 2):S79–83. Ince D, Zhang X, et al. 2003. Activity of and resistance to moxiﬂoxacin in Staphylococcus aureus. Antimicrob Agents Chemother, 47:1410–5. Jacoby GA. 2005. Mechanisms of resistance to quinolones. Clin Infect Dis, 41(Suppl 2):S120–6. John T, Velotta E. 2005. Nontuberculous (atypical) mycobacterial kera- titis after LASIK: current status and clinical implications. Cornea, 24:245–55. Kampougeris G, Antoniadou A, et al. 2005. Penetration of moxiﬂoxacin into the human aqueous humour after oral administration. Br J Ophthalmol, 89:628–31. Karp CL, Tuli SS, et al. 2003. Infectious keratitis after LASIK. Ophthalmology, 110:503–10. Katz HR, Masket S, et al. 2005. Absorption of topical moxiﬂoxacin ophthalmic solution into human aqueous humor. Cornea, 24:955–8. Kaufman SC, Rusinek C, et al. 2006. Comparison of the biocompatibility of gatiﬂoxacin 0.3% and moxiﬂoxacin 0.5%. Cornea, 25(9 Suppl 2): S31–4. Keating GM, Scott LJ. 2004. Moxiﬂoxacin: a review of its use in the man- agement of bacterial infections. Drugs, 64:2347–77. Kim DH, Stark WJ, et al. 2005a. Ocular penetration of moxiﬂoxacin 0.5% and gatiﬂoxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. Curr Med Res Opin, 21:93–4. Kim DH, Stark WJ, et al. 2005b. Aqueous penetration and biological activity of moxiﬂoxacin 0.5% ophthalmic solution and gatiﬂoxacin 0.3% solu- tion in cataract surgery patients. Ophthalmology, 112:1992–6. Kleinmann G, Larson S, et al. 2006. Intraocular concentrations of gatiﬂoxacin and moxiﬂoxacin in the anterior chamber via diffusion through the cornea using collagen shields. Cornea, 25:209–13. Koch HR, Kulus SC, et al. 2005. Corneal penetration of ﬂuoroquinolones: aqueous humor concentrations after topical application of levo- ﬂoxacin 0.5% and oﬂoxacin 0.3% eyedrops. J Cataract Refract Surg, 31:1377–85. Kotlus BS, Wymbs RA, et al. 2006. In vitro activity of ﬂuoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococ- cus aureus ocular isolates. Am J Ophthalmol, 142:726–9. 89